April 2 Quick Takes: Horizon takes out Curzion; plus Rgenta, Merck, Novartis-Aurobindo, Kite, Teneobio and Seattle Genetics

Horizon gains sclerosis candidate via Curzion deal
Horizon Therapeutics plc (NASDAQ:HZNP) acquired privately held Curzion Pharmaceuticals Inc., giving it LPAR1 antagonist HZN-825 (CZN001). Curzion’s shareholders received $45 million up front and are eligible for milestones of undisclosed size. CZN001 has completed a Phase

Read the full 420 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE